12 results on '"Starmans, M."'
Search Results
2. Validation of two frailty questionnaires in older patients with rheumatoid arthritis: a cross-sectional study
- Author
-
Oetsma, S., Boonen, A., Starmans, M., Peeters, R., van Onna, M., RS: CAPHRI - R3 - Functioning, Participating and Rehabilitation, Interne Geneeskunde, and MUMC+: MA Reumatologie (9)
- Subjects
rheumatoid arthritis ,comorbidity ,disease ,ageing ,heart-failure ,indicator ,DISABILITY ,prevalence ,frailty ,ADULTS - Abstract
ObjectivesSeveral questionnaires exist to assess frailty, a geriatric syndrome. None of these has been validated in older patients with rheumatoid arthritis (RA). Our objective was to assess aspects of validity of two frailty questionnaires: Groningen Frailty Indicator (GFI) and Geriatric 8 (G8) among RA patients.MethodsIn a cross-sectional study among patients >= 65 years information was collected on socio-demographics, disease characteristics including comorbidities and physical function and on frailty using the GFI and G8. Content validity was assessed by linking items of the GFI and G8 to the International Classification of Functioning, Disability and Health (ICF). Classic psychometric methods were used to test hypotheses on construct validity and interpretability.ResultsEighty patients (74.6 years (SD 5.9); 66% female) participated. The GFI has more items on social and mental functions; the G8 more on functions of the digestive system (e.g. nutritional status). As hypothesised, correlations (r) with physical function (R-GFI=0.54; R-G8=0.56) and disease activity (R-GFI=0.24; R-G8=0.36) were moderate to weak. However, correlations with age (R-GFI=0.20; R-G8=0.11) or comorbidities (RGFI=0.30; R-G8=0.16) were lower than expected. Instrument-specific thresholds classified 43 (54%) of participants as frail on the GFI and 44 (55%) on the G8; 33 (41%) were frail on both instruments.ConclusionsThe GFI and G8 differ in content with more emphasis on nutritional status for the G8. Both instruments are insensitive to age and comorbidities. Before deciding on their usefulness in RA, their predictive validity for mortality and resource utilisation independent of disease activity and physical function should be further evaluated.
- Published
- 2020
3. The prognostic value of hypoxia, proliferation and radiation sensitivity gene signatures: Toward a 'molecular treatment planning system'
- Author
-
Starmans, M, Begg, A, Seigneuric, R, Buffa, F, Harris, A, Wouters, B, and Lambin, P
- Published
- 2016
4. Independent and functional validation of a multi-tumour-type proliferation signature
- Author
-
Starmans, M H W, primary, Lieuwes, N G, additional, Span, P N, additional, Haider, S, additional, Dubois, L, additional, Nguyen, F, additional, van Laarhoven, H W, additional, Sweep, F C G J, additional, Wouters, B G, additional, Boutros, P C, additional, and Lambin, P, additional
- Published
- 2012
- Full Text
- View/download PDF
5. Physical activity and body composition in patients with ankylosing spondylitis
- Author
-
Plasqui, G., primary, Boonen, A., additional, Geusens, P., additional, Kroot, E. J., additional, Starmans, M., additional, and van der Linden, S., additional
- Published
- 2011
- Full Text
- View/download PDF
6. Re: Gene Expression-Based Prognostic Signatures in Lung Cancer: Ready for Clinical Use?
- Author
-
Boutros, P. C., primary, Pintilie, M., additional, John, T., additional, Starmans, M. H. W., additional, Der, S. D., additional, Shepherd, F. A., additional, Tsao, M.-S., additional, and Jurisica, I., additional
- Published
- 2010
- Full Text
- View/download PDF
7. Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types
- Author
-
Starmans, M H W, primary, Krishnapuram, B, additional, Steck, H, additional, Horlings, H, additional, Nuyten, D S A, additional, van de Vijver, M J, additional, Seigneuric, R, additional, Buffa, F M, additional, Harris, A L, additional, Wouters, B G, additional, and Lambin, P, additional
- Published
- 2008
- Full Text
- View/download PDF
8. Physical activity and body composition in patients with ankylosing spondylitis.
- Author
-
Plasqui, G., Boonen, A., Geusens, P., Kroot, E. J., Starmans, M., and van der Linden, S.
- Abstract
Objective Patients with ankylosing spondylitis (AS) are at risk for accelerated muscle loss and reduced physical activity. Accurate data are needed on body composition and physical activity in this patient group. The purpose of this study was to investigate body composition and objectively assessed physical activity in patients with AS. Methods Twenty-five AS patients (15 men, mean ± SD age 48 ± 11 years) were compared with 25 healthy adults matched for age, sex, and body mass index. Body composition was measured using a 3-compartment model based on air-displacement plethysmography to assess body volume and deuterium dilution to assess total body water. The fat-free mass index (FFMI; fat-free mass divided by height squared) and the percent fat mass (%FM) were calculated. Daily physical activity was assessed for 7 days using a triaxial accelerometer and physical fitness with an incremental test until exertion on a bicycle ergometer. Blood samples were taken to determine C-reactive protein (CRP) level and tumor necrosis factor α. Results Accelerometer output (kilocounts/day) showed the same physical activity level for patients and controls (mean ± SD 319 ± 105 versus 326 ± 66). There was no difference in the FFMI or %FM between the patients and controls. Physical activity was positively related to the FFMI (partial R = 0.38, P = 0.01) and inversely related to CRP level (R = −0.39, P < 0.01), independent of group. CRP level was inversely related to the FFMI, but the effect was less strong than with physical activity (partial R = −0.31, P = 0.03). Conclusion Daily physical activity may help preserve fat-free mass in patients with AS. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
9. Changes in Management After 18 F-DCFPyL PSMA PET in Patients Undergoing Postprostatectomy Radiotherapy, with Early Biochemical Response Outcomes.
- Author
-
Ng M, Guerrieri M, Wong LM, Taubman K, Sutherland T, Benson A, Byrne G, Koschel S, Yap K, Starmans M, Ong G, Macleod C, Foo M, and Chao M
- Subjects
- Androgen Antagonists, Androgens, Fluorine Radioisotopes, Gallium Radioisotopes, Humans, Male, Neoplasm Recurrence, Local radiotherapy, Oligopeptides, Positron Emission Tomography Computed Tomography methods, Prospective Studies, Prostatectomy, Prostate-Specific Antigen, Prostatic Neoplasms diagnostic imaging, Prostatic Neoplasms radiotherapy, Prostatic Neoplasms surgery
- Abstract
Prostate-specific membrane antigen (PSMA) tracers have increased sensitivity in the detection of prostate cancer, compared with conventional imaging. We assessed the management impact of
18 F-DCFPyL PSMA PET/CT in patients with prostate-specific antigen (PSA) recurrence after radical prostatectomy (RP) and report early biochemical response in patients who underwent radiation treatment. Methods: One hundred patients were enrolled into a prospective study, with a prior RP for prostate cancer, a PSA of 0.2-2.0 ng/mL, and no prior treatment. All patients underwent diagnostic CT and PSMA PET/CT, and management intent was completed at 3 time points (original, post-CT, and post-PSMA) and compared. Patients who underwent radiotherapy with 6-mo PSA response data are presented. Results: Ninety-eight patients are reported, with a median PSA of 0.32 ng/mL (95% CI, 0.28-0.36), pT3a/b disease in 71.4%, and an International Society of Urological Pathology grade group of at least 3 in 59.2%. PSMA PET/CT detected disease in 46.9% of patients, compared with 15.5% using diagnostic CT (PSMA PET, 29.2% local recurrence and 29.6% pelvic nodal disease). A major change in management intent was higher after PSMA than after CT (12.5% vs. 3.2%, P = 0.010), as was a moderate change in intent (31.3% vs. 13.7%, P = 0.001). The most common change was an increase in the recommendation for elective pelvic radiation (from 15.6% to 33.3%), nodal boost (from 0% to 22.9%), and use of concurrent androgen deprivation therapy (ADT) (from 22.9% to 41.7%) from original to post-PSMA intent because of detection of nodal disease. Eighty-six patients underwent18 F-DCFPyL-guided radiotherapy. Fifty-five of 86 patients either did not receive ADT or recovered after ADT, with an 18-mo PSA response from 0.32 to 0.02 ng/mL; 94.5% of patients had a PSA of no more than 0.20 ng/mL, and 74.5% had a PSA of no more than 0.03 ng/mL. Conclusion:18 F-DCFPyL PET/CT has a significant impact on management intent in patients being considered for salvage radiotherapy after RP with PSA recurrence. Increased detection of disease, particularly in the pelvic lymph nodes, resulted in increased pelvic irradiation and concurrent ADT use. Early results in patients who are staged with18 F-DCFPyL PET/CT show a favorable PSA response., (© 2022 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2022
- Full Text
- View/download PDF
10. Effect of digital-enabled multidisciplinary therapy conferences on efficiency and quality of the decision making in prostate cancer care.
- Author
-
Ronmark E, Hoffmann R, Skokic V, de Klerk-Starmans M, Jaderling F, Vos P, Gayet MCW, Hofstraat H, Janssen M, Akre O, and Vincent PH
- Subjects
- Decision Making, Humans, Male, Prospective Studies, Patient Care Team, Prostatic Neoplasms therapy
- Abstract
Objectives: To investigate the impact on efficiency and quality of preprostatectomy multidisciplinary therapy conferences (MDT) at Karolinska University Hospital related to the use of a digital solution compared with standard of care. Further, to explore whether gains in MDT efficiency and quality impact oncological or functional patient outcomes., Methods: We conducted a prospective, observational study of preoperative prostate cancer MDT at Karolinska between February 2017 and March 2021, including 1329 patients. We compared efficiency and quality of the standard MDT and the MDT using the digital solution IntelliSpace Precision Medicine Multidisciplinary Team Orchestrator (ISPM) based on the previously used MDT-MODe approach. Clinical and patient-reported functional outcomes were derived from the medical records and the Swedish National Prostate Cancer Register., Results: While ISPM was used during the MDT meeting, the time spent per patient was reduced by 24% (p<0.001) and most of the MDT-MODe items were scored significantly higher. There was a reduction in pelvic lymph-node dissection procedures in the ISPM cohort (p=0.001) and an increased proportion of unilateral nerve-sparing procedures (p=0.005), while all other outcome-related measures were not significantly different between the two patient groups., Discussion and Conclusion: To increase the value of the MDT, all data relevant for treatment decision need to be purposefully presented and compiled, which also enables secondary use of the data.The use of a digital solution during preoperative MDTs for prostate cancer decision making at Karolinska University Hospital improved the efficiency and quality of this multidisciplinary team meeting without impacting patient outcomes., Competing Interests: Competing interests: RH, MdK-S, PV, MCWG, HH and MJ are employees of Philips Research, Eindhoven, Netherlands., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
11. Validation of two frailty questionnaires in older patients with rheumatoid arthritis: a cross-sectional study.
- Author
-
Oetsma S, Boonen A, Starmans M, Peeters R, and van Onna M
- Subjects
- Aged, Cross-Sectional Studies, Female, Frail Elderly, Humans, Male, Surveys and Questionnaires, Arthritis, Rheumatoid complications, Frailty diagnosis, Geriatric Assessment
- Abstract
Objectives: Several questionnaires exist to assess frailty, a geriatric syndrome. None of these has been validated in older patients with rheumatoid arthritis (RA). Our objective was to assess aspects of validity of two frailty questionnaires: Groningen Frailty Indicator (GFI) and Geriatric 8 (G8) among RA patients., Methods: In a cross-sectional study among patients ≥65 years information was collected on socio-demographics, disease characteristics including comorbidities and physical function and on frailty using the GFI and G8. Content validity was assessed by linking items of the GFI and G8 to the International Classification of Functioning, Disability and Health (ICF). Classic psychometric methods were used to test hypotheses on construct validity and interpretability., Results: Eighty patients (74.6 years (SD 5.9); 66% female) participated. The GFI has more items on social and mental functions; the G8 more on functions of the digestive system (e.g. nutritional status). As hypothesised, correlations (r) with physical function (RGFI=0.54; RG8=0.56) and disease activity (RGFI=0.24; RG8=0.36) were moderate to weak. However, correlations with age (RGFI=0.20; RG8=0.11) or comorbidities (RGFI=0.30; RG8=0.16) were lower than expected. Instrument-specific thresholds classified 43 (54%) of participants as frail on the GFI and 44 (55%) on the G8; 33 (41%) were frail on both instruments., Conclusions: The GFI and G8 differ in content with more emphasis on nutritional status for the G8. Both instruments are insensitive to age and comorbidities. Before deciding on their usefulness in RA, their predictive validity for mortality and resource utilisation independent of disease activity and physical function should be further evaluated.
- Published
- 2020
12. Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort.
- Author
-
Rivalland G, Mitchell P, Murone C, Asadi K, Morey AL, Starmans M, Boutros PC, Walkiewicz M, Solomon B, Wright G, Knight S, and John T
- Abstract
Background: In non-small cell lung cancer (NSCLC), mesenchyme to epithelial transition (MET) protein abundance increases with disease stage and is implicated in resistance to tyrosine kinase inhibitors. To better clarify the impact of MET overexpression on tumor behavior, we investigated a large cohort of patients who underwent curative surgical resection to determine whether MET gene amplification or protein abundance was prognostic., Methods: Tissue microarrays (TMAs) were constructed using triplicate 1 mm cores of FFPE primary NSCLC specimens. TMAs underwent immunohistochemical (IHC) staining with the SP44 clone (Ventana) and cores were considered positive if >50% of tumor exhibited 2+ staining. The highest of triplicate values was used. MET gene amplification was detected using either SISH using Ventana's MET DNP probe or FISH using the D7S486/CEP 7 Abbott Probe. DNA was subjected to mutational profiling using Sequenom's LungCarta panel., Results: Data from two institutions comprising 763 patients (516; 68%) male were generated, including 360 stage I, 226 stage II, 160 stage III and 18 resected stage IV. High MET protein expression was detected in 25% (193/763), and was significantly more common in adenocarcinomas than squamous cell carcinoma (P<0.01). MET gene copy number (GCN) correlated with high MET protein expression by IHC (P=0.01). Increased MET protein expression was associated with EGFR and KRAS mutations (P<0.01 for both). Once polysomy was excluded, true MET gene amplification was detected in only 8/763 (1%) of samples. In multivariate analysis, neither MET protein abundance nor GCN were correlated to overall patient survival., Conclusions: MET expression by IHC and GCN amplification was not prognostic in this large Caucasian surgical series. MET's primary role remains as a therapeutic target., Competing Interests: Conflicts of Interest: G Rivalland reports personal fees from Astra-Zeneca, non-financial support from Roche, outside the submitted work. P Mitchell reports personal fees and other from Merck, personal fees and non-financial support from Roche, from Boehringer Ingelheim, non-financial support from Bristol Myers-Squibb, from Celgene, non-financial support and other from Astra-Zeneca, outside the submitted work. AL Morey reports speaking fees from Pfizer. B Solomon reports advisory Boards and Honoraria from Pfizer, Novartis, Roche-Genetech, AstraZeneca, BMS, and Merck. T John reports personal fees from Pfizer, personal fees from Roche, personal fees from AstraZeneca, personal fees from BMS, personal fees from Novartis, outside the submitted work. The other authors have no conflicts of interest to declare.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.